Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
Chia‐Ing Jan, Shi‐Wei Huang, Peter Canoll, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 10, pp. e003050-e003050
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

CAR-NK cells for cancer immunotherapy: from bench to bedside
Leisheng Zhang, Meng Yuan, Xiaoming Feng, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 126
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Chenyi Luo, Peipei Wang, Siqi He, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 97
Diversity of immune checkpoints in cancer immunotherapy
Zhangyan Guo, Rui Zhang, Angang Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 44
Breakthrough of solid tumor treatment: CAR-NK immunotherapy
Wenkang Wang, Yang Liu, Zhen He, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 39
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
Ke Liu, Jiajia Cui, Yan Zhan, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 66
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
Hongwen Li, Wenting Song, Zhaoming Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 58
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Yalan Zhang, Weilin Zhou, Jianping Yang, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 25
BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
Shi‐Wei Huang, Chih‐Ming Pan, Yu‐Chuan Lin, et al.
Advanced Science (2023) Vol. 10, Iss. 17
Open Access | Times Cited: 23
Advances in NK cell therapy for brain tumors
Jawad Fares, Zachary Davis, Julian S. Rechberger, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 22
The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer
Haoyu Tang, Yizhi Cao, Yiwei Zhou, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 8
Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects
Siyuan Wang, Jiaxin Wang, Yu Xia, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Xiao Wang, Xuejiao Yang, Xiang Yuan, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 33
Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
Kangdi Yang, Yuze Zhao, Guanqun Sun, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 19
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances
Tingrui Zhang, Zongguang Tai, Fengze Miao, et al.
Journal of Controlled Release (2024) Vol. 368, pp. 372-396
Closed Access | Times Cited: 7
Targeting one‐carbon metabolism for cancer immunotherapy
Xinxin Ren, Xiang Wang, Guowan Zheng, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update
Samaneh Jahandar-Lashaki, Safar Farajnia, Aref Faraji-Barhagh, et al.
Molecular Biotechnology (2024)
Closed Access | Times Cited: 5
Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
Katharina Eva Ruppel, Stephan Fricke, Ulrike Köhl, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Farhoodeh Ghaedrahmati, Nafiseh Esmaeil, Maryam Abbaspour
Cancer Communications (2022) Vol. 43, Iss. 2, pp. 177-213
Open Access | Times Cited: 23
The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy
Ruonan Li, Lili Cao
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges
Jun Kong, Mohammad Auwal Sa’ad, Hema Manusri Vijayan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer
Yu‐Chuan Lin, Mei‐Chih Chen, Shi‐Wei Huang, et al.
Advanced Science (2024) Vol. 11, Iss. 41
Open Access | Times Cited: 5
Cancer and Secretomes: HLA-G and Cancer Puzzle
Figen Abatay Sel, Fatma Savran Oğuz
Advances in experimental medicine and biology (2025)
Closed Access
JNJ-78306358, a First-in-Class Bispecific T Cell Engaging Antibody targeting CD3 and HLA-G
Nataša Obermajer, Adam Zwolak, Kelly Van De Ven, et al.
iScience (2025) Vol. 28, Iss. 3, pp. 111876-111876
Open Access
Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma
Khloe S. Gordon, Caleb R. Perez, Andrea Garmilla, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e009574-e009574
Open Access
CAR-NK cell therapy: promise and challenges in solid tumors
Sahar Balkhi, Gaia Zuccolotto, Antimo Di Spirito, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top